Ahmed Zaghloul – CEO, October Pharma, Egypt
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
October Pharma (OP) S.A.E is an Egyptian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
October Pharma (OP) is producing different pharmaceutical dosage forms of products under cGMP rules & regulations:
Solid (tablets, capsules & powder)
Liquid (syrup, drops, solution & spay)
Subcontract (Toll Out Manufacturing) for:
Soft Gelatin Capsules
Ampoule & Vial
Cream & Suppository
Powder
Contact
Piece #190, St. #25, 1st industrial zone,
6 October city. Cairo, Egypt
Tel: 38201832 / 38201652 / 38201329
Fax: +02 38201653
Email: info@octoberpharma.com
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
“My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges…
The latest news from Egyptian healthcare and life sciences, including progress towards the launch of a massive new oncology hospital, why local manufacturer EIPICO is expanding into Kazakhstan, increased governmental…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
See our Cookie Privacy Policy Here
